Once-daily roflumilast cream 0.05% is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 years, according ...
Patients with atopic dermatitis (AD) who achieve completely clear skin with tapinarof (Vtama) cream maintain low disease ...
Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream ...
Lawrence F. Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the effectiveness of ruxolitinib cream as a nonsteroidal topical treatment for atopic ...
Atopic dermatitis disease activity remained mild after patients treated with Vtama cream 1% achieved nearly 80 consecutive ...
Data demonstrated favorable safety and local tolerability of ZORYVE® (roflumilast) cream 0.15% in adults and children with atopic dermatitis (AD) ...
Approximately 35 million individuals in the U.S. suffer from atopic dermatitis and psoriasis, highlighting a substantial market opportunity for ZORYVE products. Recognition of ZORYVE cream for ...
A break from treatment with Vtama won’t lead to worsening of patients’ atopic dermatitis, finds a new analysis of an ...
The reduction in itch was the greatest contributor to quality-of-life improvement for adolescents and adults with atopic ...
Once-daily roflumilast cream 0.05 percent is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 ye ...